CTI BioPharma Corp Company Profile (NASDAQ:CTIC)

About CTI BioPharma Corp (NASDAQ:CTIC)

CTI BioPharma Corp logoCTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (ISTs), such as the ongoing maintenance therapy trial in patients with ovarian cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CTIC
  • CUSIP: N/A
  • Web: www.ctibiopharma.com
Capitalization:
  • Market Cap: $116.95 million
  • Outstanding Shares: 28,045,000
Average Prices:
  • 50 Day Moving Avg: $4.13
  • 200 Day Moving Avg: $3.33
  • 52 Week Range: $3.07 - $6.48
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.74
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $21.68 million
  • Price / Sales: 5.39
  • Book Value: ($0.17) per share
  • Price / Book: -24.53
Profitability:
  • EBIDTA: ($76,690,000.00)
  • Net Margins: -119.60%
  • Return on Equity: -188.29%
  • Return on Assets: -64.52%
Debt:
  • Debt-to-Equity Ratio: 1.07%
  • Current Ratio: 1.47%
  • Quick Ratio: 1.41%
Misc:
  • Average Volume: 74,979 shs.
  • Beta: 0.96
  • Short Ratio: 12.29
 

Frequently Asked Questions for CTI BioPharma Corp (NASDAQ:CTIC)

What is CTI BioPharma Corp's stock symbol?

CTI BioPharma Corp trades on the NASDAQ under the ticker symbol "CTIC."

When did CTI BioPharma Corp's stock split? How did CTI BioPharma Corp's stock split work?

Shares of CTI BioPharma Corp reverse split on Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 30th 2016. An investor that had 100 shares of CTI BioPharma Corp stock prior to the reverse split would have 10 shares after the split.

How were CTI BioPharma Corp's earnings last quarter?

CTI BioPharma Corp (NASDAQ:CTIC) released its earnings results on Wednesday, May, 3rd. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.70) by $0.01. The firm had revenue of $0.75 million for the quarter. CTI BioPharma Corp had a negative return on equity of 188.29% and a negative net margin of 119.60%. View CTI BioPharma Corp's Earnings History.

When will CTI BioPharma Corp make its next earnings announcement?

CTI BioPharma Corp is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for CTI BioPharma Corp.

Where is CTI BioPharma Corp's stock going? Where will CTI BioPharma Corp's stock price be in 2017?

1 equities research analysts have issued 12 month price targets for CTI BioPharma Corp's stock. Their forecasts range from $7.50 to $7.50. On average, they expect CTI BioPharma Corp's share price to reach $7.50 in the next twelve months. View Analyst Ratings for CTI BioPharma Corp.

Who are some of CTI BioPharma Corp's key competitors?

Who owns CTI BioPharma Corp stock?

CTI BioPharma Corp's stock is owned by a number of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.90%), Renaissance Technologies LLC (0.43%), Geode Capital Management LLC (0.42%), Morgan Stanley (0.21%), Jane Street Group LLC (0.20%) and United Capital Financial Advisers LLC (0.19%). Company insiders that own CTI BioPharma Corp stock include Jack W Singer, James A Bianco, Louis A Bianco, Matthew Plunkett, Richard L Love and Value Fund L P Biotechnology. View Institutional Ownership Trends for CTI BioPharma Corp.

Who sold CTI BioPharma Corp stock? Who is selling CTI BioPharma Corp stock?

CTI BioPharma Corp's stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Renaissance Technologies LLC, Goldman Sachs Group Inc., Geode Capital Management LLC, United Capital Financial Advisers LLC, Blair William & Co. IL, Tiedemann Wealth Management LLC and California Public Employees Retirement System. View Insider Buying and Selling for CTI BioPharma Corp.

Who bought CTI BioPharma Corp stock? Who is buying CTI BioPharma Corp stock?

CTI BioPharma Corp's stock was acquired by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Nine Chapters Capital Management LLC, Segantii Capital Management Ltd and Morgan Stanley. View Insider Buying and Selling for CTI BioPharma Corp.

How do I buy CTI BioPharma Corp stock?

Shares of CTI BioPharma Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of CTI BioPharma Corp stock cost?

One share of CTI BioPharma Corp stock can currently be purchased for approximately $4.17.

Analyst Ratings

Consensus Ratings for CTI BioPharma Corp (NASDAQ:CTIC) (?)
Ratings Breakdown: 1 Hold Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $7.50 (79.86% upside)

Analysts' Ratings History for CTI BioPharma Corp (NASDAQ:CTIC)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/29/2016Piper Jaffray CompaniesReiterated RatingNeutral$7.50N/AView Rating Details
2/10/2016Ladenburg Thalmann Financial ServicesDowngradeBuy -> NeutralN/AView Rating Details
2/10/2016WallachBeth CapitalDowngradeHold -> SellN/AView Rating Details
2/8/2016S&P Equity ResearchLower Price Target$4.80 -> $3.90N/AView Rating Details
8/14/2015Roth CapitalReiterated RatingBuy$45.00N/AView Rating Details
6/1/2015Janney Montgomery ScottReiterated RatingBuy -> Fair Value$35.00 -> $19.40N/AView Rating Details
(Data available from 5/26/2015 forward)

Earnings

Earnings History for CTI BioPharma Corp (NASDAQ:CTIC)
Earnings by Quarter for CTI BioPharma Corp (NASDAQ:CTIC)
Earnings History by Quarter for CTI BioPharma Corp (NASDAQ:CTIC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2017        
5/3/2017Q1 2017($0.70)($0.71)$0.75 millionViewListenView Earnings Details
3/2/2017Q4 2016($0.70)($0.23)$9.14 millionViewListenView Earnings Details
8/4/2016Q2($0.10)($0.07)$7.36 millionViewN/AView Earnings Details
5/10/2016Q1($0.04)$0.01$36.48 millionViewN/AView Earnings Details
2/16/2016Q4($0.18)($0.13)$11.32 millionViewN/AView Earnings Details
11/5/2015Q315($0.12)($0.19)$18.89 million$1.00 millionViewListenView Earnings Details
8/6/2015Q215($0.10)($0.19)$12.77 million$1.10 millionViewListenView Earnings Details
5/6/2015Q115($0.14)($0.16)$9.84 million$2.73 millionViewListenView Earnings Details
3/12/2015Q414($0.18)($0.27)$2.48 million$17.80 millionViewListenView Earnings Details
10/29/2014Q3$0.03$0.03$21.52 million$39.53 millionViewListenView Earnings Details
8/4/2014Q2($0.12)($0.19)$11.79 million$1.34 millionViewListenView Earnings Details
4/29/2014Q114($0.20)($0.20)$1.10 million$1.40 millionViewN/AView Earnings Details
3/4/2014Q4($0.16)$0.08$1.26 million$32.90 millionViewListenView Earnings Details
2/28/2013Q4 2012($0.20)($0.20)$1.00 millionViewListenView Earnings Details
11/1/2012Q312($0.38)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for CTI BioPharma Corp (NASDAQ:CTIC)
Current Year EPS Consensus Estimate: $-2.40 EPS
Next Year EPS Consensus Estimate: $-2.40 EPS

Dividends

Dividend History for CTI BioPharma Corp (NASDAQ:CTIC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for CTI BioPharma Corp (NASDAQ:CTIC)
Insider Ownership Percentage: 3.01%
Insider Trades by Quarter for CTI BioPharma Corp (NASDAQ:CTIC)
Institutional Ownership by Quarter for CTI BioPharma Corp (NASDAQ:CTIC)
Insider Trades by Quarter for CTI BioPharma Corp (NASDAQ:CTIC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/24/2016James A BiancoCEOSell10,000$0.37$3,700.00View SEC Filing  
5/27/2016James A BiancoCEOSell10,000$0.45$4,500.00View SEC Filing  
4/29/2016James A BiancoCEOSell10,000$0.52$5,200.00View SEC Filing  
3/28/2016James A BiancoCEOSell10,000$0.49$4,900.00View SEC Filing  
3/21/2016James A BiancoCEOSell318,169$0.55$174,992.95View SEC Filing  
3/4/2016Matthew PlunkettEVPSell10,000$0.59$5,900.00View SEC Filing  
2/26/2016Jack W SingerEVPSell15,000$0.63$9,450.00View SEC Filing  
2/26/2016James A BiancoCEOSell10,000$0.63$6,300.00View SEC Filing  
2/16/2016James A BiancoCEOSell100,000$0.42$42,000.00View SEC Filing  
2/4/2016Matthew PlunkettEVPSell10,000$1.15$11,500.00View SEC Filing  
1/29/2016Jack W. SingerEVPSell15,000$1.18$17,700.00View SEC Filing  
1/29/2016James A BiancoCEOSell10,000$1.20$12,000.00View SEC Filing  
1/8/2016Value Fund L P BiotechnologyInsiderBuy1,001,327$1.22$1,221,618.94View SEC Filing  
1/4/2016Matthew PlunkettEVPSell10,000$1.21$12,100.00View SEC Filing  
12/30/2015James A. BiancoCEOSell110,000$1.26$138,600.00View SEC Filing  
12/28/2015James A. BiancoCEOSell10,000$1.29$12,900.00View SEC Filing  
12/18/2015Jack W. SingerEVPSell15,000$1.18$17,700.00View SEC Filing  
12/4/2015Matthew PlunkettEVPSell10,000$1.00$10,000.00View SEC Filing  
11/27/2015Jack W. SingerEVPSell15,000$1.21$18,150.00View SEC Filing  
11/27/2015James A BiancoCEOSell10,000$1.23$12,300.00View SEC Filing  
11/19/2015Louis A. BiancoEVPSell15,000$1.13$16,950.00View SEC Filing  
10/30/2015James A BiancoCEOSell260,000$1.35$351,000.00View SEC Filing  
10/29/2015Louis A. BiancoEVPSell10,000$1.41$14,100.00View SEC Filing  
10/23/2015Jack W. SingerEVPSell15,000$1.62$24,300.00View SEC Filing  
10/22/2015Louis A BiancoEVPSell10,000$1.58$15,800.00View SEC Filing  
10/5/2015Matthew PlunkettEVPSell10,000$1.52$15,200.00View SEC Filing  
9/30/2015Jack W. SingerEVPSell100,000$1.42$142,000.00View SEC Filing  
9/30/2015James A. BiancoCEOSell600,000$1.43$858,000.00View SEC Filing  
9/30/2015Richard L. LoveDirectorSell13,660$1.45$19,807.00View SEC Filing  
9/29/2015Louis A. BiancoEVPSell170,000$1.41$239,700.00View SEC Filing  
9/25/2015Jack W. SingerEVPSell15,000$1.64$24,600.00View SEC Filing  
9/24/2015Matthew PlunkettEVPSell75,869$1.57$119,114.33View SEC Filing  
9/4/2015Matthew PlunkettEVPSell10,000$1.54$15,400.00View SEC Filing  
8/28/2015Jack W. SingerEVPSell15,000$1.58$23,700.00View SEC Filing  
7/24/2015Jack W SingerEVPSell15,000$1.91$28,650.00View SEC Filing  
7/23/2015Louis A BiancoEVPSell10,000$1.91$19,100.00View SEC Filing  
7/6/2015Matthew PlunkettEVPSell10,000$1.95$19,500.00View SEC Filing  
6/26/2015Jack W SingerEVPSell15,000$2.07$31,050.00View SEC Filing  
6/25/2015Louis A BiancoEVPSell10,000$2.18$21,800.00View SEC Filing  
6/4/2015Matthew PlunkettEVPSell10,000$2.06$20,600.00View SEC Filing  
5/22/2015Jack W SingerEVPSell15,000$1.74$26,100.00View SEC Filing  
5/21/2015Louis A BiancoEVPSell10,000$1.80$18,000.00View SEC Filing  
5/4/2015Matthew PlunkettEVPSell10,000$1.86$18,600.00View SEC Filing  
4/24/2015Jack W SingerEVPSell15,000$1.96$29,400.00View SEC Filing  
4/23/2015Louis A BiancoEVPSell10,000$1.93$19,300.00View SEC Filing  
4/6/2015Matthew PlunkettEVPSell16,569$1.88$31,149.72View SEC Filing  
3/23/2015James A BiancoCEOSell175,199$1.95$341,638.05View SEC Filing  
3/23/2015Matthew PlunkettEVPSell59,130$1.96$115,894.80View SEC Filing  
3/20/2015Louis A BiancoEVPSell63,000$1.94$122,220.00View SEC Filing  
2/27/2015Jack W SingerEVPSell15,000$2.35$35,250.00View SEC Filing  
2/5/2015Louis A BiancoEVPSell10,000$2.22$22,200.00View SEC Filing  
2/4/2015Matthew PlunkettEVPSell12,000$2.22$26,640.00View SEC Filing  
1/8/2015Louis A BiancoEVPSell10,000$2.32$23,200.00View SEC Filing  
1/5/2015Matthew PlunkettEVPSell12,000$2.36$28,320.00View SEC Filing  
12/19/2014James A BiancoCEOSell40,000$2.44$97,600.00View SEC Filing  
12/4/2014Louis A BiancoEVPSell10,000$2.25$22,500.00View SEC Filing  
11/6/2014Louis A BiancoEVPSell10,000$2.37$23,700.00View SEC Filing  
10/6/2014Matthew PlunkettEVPSell12,000$2.39$28,680.00View SEC Filing  
9/23/2014Matthew PlunkettEVPSell103,635$2.56$265,305.60View SEC Filing  
9/22/2014James A BiancoCEOSell307,068$2.53$776,882.04View SEC Filing  
9/22/2014Matthew PlunkettEVPSell51,817$2.58$133,687.86View SEC Filing  
9/19/2014Louis A BiancoEVPSell145,000$2.59$375,550.00View SEC Filing  
9/4/2014Matthew PlunkettEVPSell27,301$2.48$67,706.48View SEC Filing  
8/15/2014James A BiancoCEOSell40,000$2.54$101,600.00View SEC Filing  
8/4/2014Matthew PlunkettEVPSell12,000$2.48$29,760.00View SEC Filing  
7/10/2014Louis A BiancoEVPSell10,000$2.73$27,300.00View SEC Filing  
7/7/2014Matthew PlunkettEVPSell12,000$2.89$34,680.00View SEC Filing  
6/27/2014James A BiancoCEOSell50,000$2.84$142,000.00View SEC Filing  
6/5/2014Louis A BiancoEVPSell10,000$2.97$29,700.00View SEC Filing  
5/1/2014Louis BiancoEVPSell10,000$2.91$29,100.00View SEC Filing  
3/28/2014Vartan GregorianDirectorSell82,000$3.41$279,620.00View SEC Filing  
3/25/2014Phillip Phd NudelmanDirectorSell100,000$3.56$356,000.00View SEC Filing  
3/24/2014Jack SingerEVPSell60,000$3.47$208,200.00View SEC Filing  
3/21/2014James BiancoCEOSell395,000$3.83$1,512,850.00View SEC Filing  
3/21/2014Matthew PlunkettEVPSell170,000$3.73$634,100.00View SEC Filing  
3/7/2014Fred TellingDirectorSell72,095$3.75$270,356.25View SEC Filing  
9/23/2013James A BiancoCEOSell130,551$1.50$195,826.50View SEC Filing  
8/30/2013James A BiancoCEOSell25,925$1.08$27,999.00View SEC Filing  
8/9/2013James A BiancoCEOSell40,000$1.07$42,800.00View SEC Filing  
8/7/2013Mary Oneil MundingerDirectorSell125,000$1.06$132,500.00View SEC Filing  
8/6/2013Phillip M Phd NudelmanDirectorSell50,000$1.09$54,500.00View SEC Filing  
7/26/2013James A BiancoCEOSell25,688$1.09$27,999.92View SEC Filing  
6/28/2013James A BiancoCEOSell26,053$1.08$28,137.24View SEC Filing  
6/5/2013Jack W SingerEVPSell10,000$1.26$12,600.00View SEC Filing  
5/31/2013James A BiancoCEOSell28,000$1.22$34,160.00View SEC Filing  
5/31/2013Louis A BiancoEVPSell33,712$1.24$41,802.88View SEC Filing  
5/30/2013Fred TellingDirectorSell64,798$1.24$80,349.52View SEC Filing  
5/24/2013Richard L LoveDirectorSell23,000$1.21$27,830.00View SEC Filing  
5/10/2013James A BiancoCEOSell25,000$1.16$29,000.00View SEC Filing  
5/9/2013Louis A BiancoEVPSell50,000$1.15$57,500.00View SEC Filing  
3/11/2013Jack W SingerEVPSell13,000$1.28$16,640.00View SEC Filing  
8/10/2012James A BiancoCEOSell10,000$0.42$4,200.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for CTI BioPharma Corp (NASDAQ:CTIC)
Latest Headlines for CTI BioPharma Corp (NASDAQ:CTIC)
Source:
DateHeadline
finance.yahoo.com logoETFs with exposure to CTI BioPharma Corp. : May 25, 2017
finance.yahoo.com - May 25 at 6:14 PM
americanbankingnews.com logo Analysts Anticipate CTI BioPharma Corp (CTIC) Will Post Earnings of -$0.70 Per Share
www.americanbankingnews.com - May 12 at 8:30 PM
finance.yahoo.com logoETFs with exposure to CTI BioPharma Corp. : May 8, 2017
finance.yahoo.com - May 8 at 9:26 PM
finance.yahoo.com logoCTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q1, 2017 By the Numbers : May 5, 2017
finance.yahoo.com - May 5 at 4:48 PM
rttnews.com logoEARNINGS SUMMARY: Details of CTI BioPharma Corp. Q1 Earnings Report
www.rttnews.com - May 5 at 2:44 AM
americanbankingnews.com logoCTI BioPharma Corp (CTIC) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 4 at 9:02 PM
finance.yahoo.com logoCTI BioPharma reports 1Q loss - Yahoo Finance
finance.yahoo.com - May 4 at 7:09 AM
finance.yahoo.com logoEdited Transcript of CTIC earnings conference call or presentation 3-May-17 8:30pm GMT
finance.yahoo.com - May 4 at 7:09 AM
finance.yahoo.com logoCTI BioPharma reports 1Q loss
finance.yahoo.com - May 3 at 9:30 PM
prnewswire.com logoCTI BioPharma Reports First Quarter 2017 Financial Results - PR Newswire (press release)
www.prnewswire.com - May 3 at 4:30 PM
finance.yahoo.com logoCTI BioPharma Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 3 at 4:30 PM
americanbankingnews.com logoCTI BioPharma Corp (CTIC) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 1 at 3:16 PM
americanbankingnews.com logoCTI BioPharma Corp (CTIC) Earning Favorable Press Coverage, Report Finds
www.americanbankingnews.com - April 28 at 9:51 AM
finance.yahoo.com logoETFs with exposure to CTI BioPharma Corp. : April 26, 2017
finance.yahoo.com - April 27 at 1:55 AM
finance.yahoo.com logoCTI BioPharma to Report First Quarter 2017 Financial Results on May 3, 2017
finance.yahoo.com - April 27 at 1:55 AM
finance.yahoo.com logoServier and CTI BioPharma Expand License and Collaboration Agreement to Develop and Commercialize PIXUVRI®
finance.yahoo.com - April 25 at 12:00 PM
americanbankingnews.com logo-$0.70 Earnings Per Share Expected for CTI BioPharma Corp (CTIC) This Quarter
www.americanbankingnews.com - April 24 at 12:31 PM
finance.yahoo.com logoEdited Transcript of CTIC earnings conference call or presentation 2-Mar-17 9:30pm GMT
finance.yahoo.com - March 31 at 4:41 PM
fool.com logoCTI BioPharma CTIC
www.fool.com - March 30 at 4:58 PM
finance.yahoo.com logoCTI BIOPHARMA CORP Financials
finance.yahoo.com - March 8 at 5:19 PM
finance.yahoo.com logoCTI BioPharma to Present at the 29th Annual ROTH Conference
finance.yahoo.com - March 8 at 2:33 AM
rttnews.com logoEARNINGS SUMMARY: Details of CTI BioPharma Corp. Q4 Earnings Report
www.rttnews.com - March 2 at 4:50 PM
us.rd.yahoo.com logoCTI BioPharma Reports Fourth Quarter and Full Year 2016 Financial Results
us.rd.yahoo.com - March 2 at 4:50 PM
biz.yahoo.com logoCTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi
us.rd.yahoo.com - March 2 at 4:50 PM
biz.yahoo.com logoQ4 2016 CTi Biopharma Corp Earnings Release - After Market Close
biz.yahoo.com - March 2 at 9:46 AM
biz.yahoo.com logoCTi Biopharma Corp Earnings Call scheduled for 4:30 pm ET today
biz.yahoo.com - March 2 at 9:46 AM
bizjournals.com logoCTI BioPharma hires new CEO
www.bizjournals.com - March 1 at 6:24 PM
rttnews.com logoCTI BioPharma Appoints Adam Craig As President & CEO - Quick Facts
www.rttnews.com - February 27 at 5:39 PM
streetinsider.com logoCTI BioPharma (CTIC) Names Adam Craig as President and CEO
www.streetinsider.com - February 27 at 5:39 PM
us.rd.yahoo.com logoCTI BioPharma Announces Appointment of Hematology/Oncology Clinical Expert Adam Craig, M.D., Ph.D., as President and CEO
us.rd.yahoo.com - February 27 at 5:39 PM
us.rd.yahoo.com logo5:12 am CTI BioPharma names Adam Craig, M.D., Ph.D., as President and CEO effective March 20
us.rd.yahoo.com - February 27 at 5:39 PM
biz.yahoo.com logoCTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Finan
biz.yahoo.com - February 27 at 5:39 PM
prnewswire.com logoCTI BioPharma to Report Fourth Quarter and Full Year 2016 Financial Results on March 2, 2017 - PR Newswire (press release)
www.prnewswire.com - February 23 at 2:49 AM
finance.yahoo.com logoCTI BioPharma to Report Fourth Quarter and Full Year 2016 Financial Results on March 2, 2017
finance.yahoo.com - February 23 at 2:49 AM
seekingalpha.com logoCTI BioPharma (CTIC) Presents At 19th Annual BIO CEO & Investor Conference - Slideshow
seekingalpha.com - February 16 at 1:29 PM
finance.yahoo.com logoCTI BioPharma to Present at the BIO CEO & Investor Conference
finance.yahoo.com - February 8 at 3:43 AM
prnewswire.com logoCTI BioPharma Appoints Leading BioPharma Executive Michael ... - PR Newswire (press release)
www.prnewswire.com - January 25 at 3:16 AM
finance.yahoo.com logoCTI BioPharma Appoints Leading BioPharma Executive Michael Metzger To Board Of Directors
finance.yahoo.com - January 24 at 5:11 PM
biz.yahoo.com logoCTI BIOPHARMA CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
biz.yahoo.com - January 24 at 5:11 PM
finance.yahoo.com logo6:11 pm CTI BioPharma regained compliance with Nasdaq Listing Rule for minimum bid price; matter is now closed
finance.yahoo.com - January 20 at 10:44 PM

Social

Chart

CTI BioPharma Corp (CTIC) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by MarketBeat.com Staff